Study title: Safety and immunogenicity of Vi CPS vaccine in teenagers
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: Bacterial Infections and Mycoses [C01] | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: Purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain) | |||||
ATC code: J07AP03 | |||||
Document link: | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | Y |